Related Experiment Videos
Studying Huntington's Disease in Yeast: From Mechanisms to Pharmacological Approaches
Sebastian Hofer1, Katharina Kainz1, Andreas Zimmermann1,2
1Institute of Molecular Biosciences, University of Graz, Graz, Austria.
Insights
Budding yeast models Huntington's disease (HD) mechanisms and drug screening. This research highlights yeast's role in understanding mutant huntingtin (mHTT) cytotoxicity and finding new HD therapies.
Area of Science:
- Neuroscience
- Genetics
- Biochemistry
Background:
- Huntington's disease (HD) is a fatal neurodegenerative disorder characterized by motor, cognitive, and psychiatric impairments.
- Currently, no cure exists for HD, with treatments focusing solely on symptom management.
- The disease stems from a mutation in the huntingtin gene, leading to an expanded polyglutamine tract and protein aggregation.
Purpose of the Study:
- To summarize the contributions of yeast models to understanding Huntington's disease.
- To elucidate the mechanisms of mutant huntingtin (mHTT) cytotoxicity.
- To evaluate yeast as a platform for screening potential therapeutic agents for HD.
Main Methods:
- Utilizing the budding yeast *Saccharomyces cerevisiae* as a model organism.
- Leveraging yeast's genetic tractability and conserved cellular pathways.
- Applying yeast-based systems for mechanistic studies and drug screening.
Main Results:
- Yeast models have provided significant insights into the cellular processes underlying mHTT toxicity.
- The conserved nature of HD-relevant pathways in yeast facilitates the study of disease mechanisms.
- Yeast serves as an effective platform for high-throughput screening of compounds with therapeutic potential for HD.
Conclusions:
- *Saccharomyces cerevisiae* is a valuable tool for dissecting the molecular basis of Huntington's disease.
- Yeast-based research accelerates the identification of novel therapeutic strategies for HD.
- The use of yeast models is crucial for advancing HD research and developing effective interventions.
Abstract:
Huntington's disease (HD) is a neurodegenerative disorder that leads to progressive neuronal loss, provoking impaired motor control, cognitive decline, and dementia. So far, HD remains incurable, and available drugs are effective only for symptomatic management. HD is caused by a mutant form of the huntingtin protein, which harbors an elongated polyglutamine domain and is highly prone to aggregation. However, many aspects underlying the cytotoxicity of mutant huntingtin (mHTT) remain elusive, hindering the efficient development of applicable interventions to counteract HD. An important strategy to obtain molecular insights into human disorders in general is the use of eukaryotic model organisms, which are easy to genetically manipulate and display a high degree of conservation regarding disease-relevant cellular processes. The budding yeast Saccharomyces cerevisiae has a long-standing and successful history in modeling a plethora of human maladies and has recently emerged as an effective tool to study neurodegenerative disorders, including HD. Here, we summarize some of the most important contributions of yeast to HD research, specifically concerning the elucidation of mechanistic features of mHTT cytotoxicity and the potential of yeast as a platform to screen for pharmacological agents against HD.